Pharmacovigilance: Serious vs Severity in Drug Safety Reporting Lakkireddy Sowmya posted on the topic LinkedIn CJC 1295 and Ipamorelin: Maximizing Health Benefits The Fountain Adverse Event Reporting in Clinical Trials Sermorelin Safety Guide In 2023, the FDA banned 19 peptides from compounding pharmacies. No specific safety incident. No clear signal. Just a regulatory decision that pushed millions of patients toward gray market suppliers and overseas Adverse Event Reporting Medical School Office of Research